FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056534593> ?p ?o ?g. }

• W2056534593 endingPage "1156" @default.
• W2056534593 startingPage "1156" @default.
• W2056534593 abstract "Wang and colleagues (1) recently reported that the cardiac glycoside bufalin was a potent inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Because these coactivators have been implicated in cancer progression, the authors investigated whether bufalin could also block cancer cell growth in cell culture and animal models. They observed that bufalin inhibited the growth of human MCF-7 breast cancer cells and human A549 lung cancer cells at nanomolar concentrations (3–5 nmol/L); these concentrations also inhibited SRC-3, did not affect the growth of rodent nonmalignant TM4 Sertoli cells, and were below those reported to be tolerated by humans (8.75 nmol/L). They also found that bufalin inhibited tumor growth in mice xenotransplanted with human MDA-MB-231 breast cancer cells. The most relevant conclusion of this work is that bufalin has potential for cancer therapy.The key feature of an efficient anticancer drug is its ability to kill (or inhibit the growth of) human cancer cells at concentrations that do not significantly affect human nonmalignant cells. Clifford and Kaplan (2) have recently shown, however, that human breast nonmalignant cells were more sensitive than human breast cancer cells (MCF-7 and MDA-MB-231) to bufalin-induced cell growth inhibition and apoptosis. They showed, for instance, that 50 nmol/L bufalin induced apoptosis in human breast nonmalignant cells but not in MCF-7 and MDA-MB-231 breast cancer cells. Yan and colleagues (3) also observed low levels of apoptosis in MCF-7 and MDA-MB-231 cells exposed for 48 hours to 50 nmol/L bufalin.The inhibition of tumor growth induced by bufalin in the mouse xenograft model (1) is probably an experimental artifact (4, 5). It has been known for some time that rodent cells are much more resistant than human cells to the cytotoxic effects of bufalin and other cardiac glycosides (6). More recently, we observed that the cytotoxic activity of three cardiac glycosides in several human cell lines (originated from malignant and nonmalignant tissues) was approximately 1,000 times higher than in rodent cell lines and that the selectivity of the three cardiac glycosides toward human cancer cells versus human nonmalignant cells was variable and not higher than 10-fold (5). These studies strongly suggest that the antitumor activity of bufalin in mice xenotransplanted with human cancer cells (1) is due to interspecies differences in sensitivity and not to selective inhibition of cancer cell growth.These data do not support the idea that bufalin has potential for cancer therapy.See the Response, p. 1157No potential conflicts of interest were disclosed." @default.
• W2056534593 created "2016-06-24" @default.
• W2056534593 creator A5001682016 @default.
• W2056534593 creator A5002727700 @default.
• W2056534593 creator A5006061477 @default.
• W2056534593 creator A5046935838 @default.
• W2056534593 creator A5051071578 @default.
• W2056534593 creator A5088390075 @default.
• W2056534593 date "2015-03-03" @default.
• W2056534593 modified "2023-10-14" @default.
• W2056534593 title "Bufalin Is a Steroid Receptor Coactivator Inhibitor—Letter" @default.
• W2056534593 cites W1974940196 @default.
• W2056534593 cites W2040045061 @default.
• W2056534593 cites W2040340203 @default.
• W2056534593 cites W2048986808 @default.
• W2056534593 cites W2051884044 @default.
• W2056534593 cites W2129833757 @default.
• W2056534593 doi "https://doi.org/10.1158/0008-5472.can-14-0398" @default.
• W2056534593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25736686" @default.
• W2056534593 hasPublicationYear "2015" @default.
• W2056534593 type Work @default.
• W2056534593 sameAs 2056534593 @default.
• W2056534593 citedByCount "2" @default.
• W2056534593 countsByYear W20565345932016 @default.
• W2056534593 countsByYear W20565345932019 @default.
• W2056534593 crossrefType "journal-article" @default.
• W2056534593 hasAuthorship W2056534593A5001682016 @default.
• W2056534593 hasAuthorship W2056534593A5002727700 @default.
• W2056534593 hasAuthorship W2056534593A5006061477 @default.
• W2056534593 hasAuthorship W2056534593A5046935838 @default.
• W2056534593 hasAuthorship W2056534593A5051071578 @default.
• W2056534593 hasAuthorship W2056534593A5088390075 @default.
• W2056534593 hasBestOaLocation W20565345931 @default.
• W2056534593 hasConcept C121608353 @default.
• W2056534593 hasConcept C126322002 @default.
• W2056534593 hasConcept C134018914 @default.
• W2056534593 hasConcept C1491633281 @default.
• W2056534593 hasConcept C185592680 @default.
• W2056534593 hasConcept C190283241 @default.
• W2056534593 hasConcept C2777151579 @default.
• W2056534593 hasConcept C29537977 @default.
• W2056534593 hasConcept C502942594 @default.
• W2056534593 hasConcept C530470458 @default.
• W2056534593 hasConcept C55493867 @default.
• W2056534593 hasConcept C62112901 @default.
• W2056534593 hasConcept C71924100 @default.
• W2056534593 hasConcept C86803240 @default.
• W2056534593 hasConcept C96232424 @default.
• W2056534593 hasConcept C98274493 @default.
• W2056534593 hasConceptScore W2056534593C121608353 @default.
• W2056534593 hasConceptScore W2056534593C126322002 @default.
• W2056534593 hasConceptScore W2056534593C134018914 @default.
• W2056534593 hasConceptScore W2056534593C1491633281 @default.
• W2056534593 hasConceptScore W2056534593C185592680 @default.
• W2056534593 hasConceptScore W2056534593C190283241 @default.
• W2056534593 hasConceptScore W2056534593C2777151579 @default.
• W2056534593 hasConceptScore W2056534593C29537977 @default.
• W2056534593 hasConceptScore W2056534593C502942594 @default.
• W2056534593 hasConceptScore W2056534593C530470458 @default.
• W2056534593 hasConceptScore W2056534593C55493867 @default.
• W2056534593 hasConceptScore W2056534593C62112901 @default.
• W2056534593 hasConceptScore W2056534593C71924100 @default.
• W2056534593 hasConceptScore W2056534593C86803240 @default.
• W2056534593 hasConceptScore W2056534593C96232424 @default.
• W2056534593 hasConceptScore W2056534593C98274493 @default.
• W2056534593 hasIssue "6" @default.
• W2056534593 hasLocation W20565345931 @default.
• W2056534593 hasLocation W20565345932 @default.
• W2056534593 hasOpenAccess W2056534593 @default.
• W2056534593 hasPrimaryLocation W20565345931 @default.
• W2056534593 hasRelatedWork W1511595270 @default.
• W2056534593 hasRelatedWork W2350294409 @default.
• W2056534593 hasRelatedWork W2351136637 @default.
• W2056534593 hasRelatedWork W2355197242 @default.
• W2056534593 hasRelatedWork W2356093969 @default.
• W2056534593 hasRelatedWork W2363671651 @default.
• W2056534593 hasRelatedWork W2364535361 @default.
• W2056534593 hasRelatedWork W2372283855 @default.
• W2056534593 hasRelatedWork W2378222954 @default.
• W2056534593 hasRelatedWork W2382230817 @default.
• W2056534593 hasVolume "75" @default.
• W2056534593 isParatext "false" @default.
• W2056534593 isRetracted "false" @default.
• W2056534593 magId "2056534593" @default.
• W2056534593 workType "article" @default.